Physician profile
Allante Thomas
NPI 1750028569
$1,220.66
in general payments reported to CMS, 2019-2025
12 companies · $45.92 in 2025
The $45.92 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $375 · 2023: $491 · 2024: $203 · 2025: $45.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.32 |
| Education | $282.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $226.00 | 2023 | Tukysa |
| Incyte Corporation | $211.78 | 2022-2024 | |
| Janssen Biotech, INC. | $135.70 | 2022-2023 | Rybrevant |
| Gilead Sciences, INC. | $124.03 | 2022-2023 | |
| Novocure INC. | $113.91 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $108.80 | 2023 | Opdivo |
| Celgene Corporation | $105.72 | 2021 | |
| Alexion Pharmaceuticals, INC. | $98.71 | 2024-2025 | Soliris, Ultomiris |
| Eisai INC. | $35.05 | 2024-2025 | |
| Daiichi Sankyo INC. | $27.47 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $16.99 | 2023 | Imbruvica |
| Abbvie INC. | $16.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allante Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.